ClinicalTrials.gg
RecruitingNCT07519044IAT-GIANTUpdated Jun 24, 2026

Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion

A Phase 4 interventional study of Intravenous GM1 Therapy and Placebo Therapy in Stroke and Acute Ischemic Stroke, sponsored by Xuanwu Hospital, Beijing. Recruiting at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-24.

Primary conditionIschemic StrokeRegistry: StrokeReclassifiedWhy we changed it
Registry
Stroke — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ischemic Stroke
Why
  1. The study's listed conditions name Ischemic Stroke, a narrower term within Stroke.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Xuanwu Hospital, Beijing · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
868
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing — 30 open to participants now, 31 under way, 2 of them phase 3. Ischemic Stroke · Xuanwu Hospital, Beijing.

Planned enrollment
6th of 28
868 · median 325
Started
2026
with 9 others
Phase 4
6 of 52
2 open now
Primary completion
2027-01
later than 11 of 30 live
Registered
46th of 52
by date

Among the 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing, this one is the 6th largest by planned enrollment of the 28 interventional ones that give a count, is one of 10 that started in 2026, is one of 6 in phase 4, reaches primary completion later than 11 of the 30 other live ones, and was the 46th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

30 of the 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing are open now, in 1 country. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 30 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing, or all of them as a file.
02

Study summary

Stroke is a leading cause of global mortality and morbidity, with acute ischemic stroke (AIS) accounting for approximately 65.3% of cases and resulting in roughly 3.4 million new cases annually in China. While endovascular thrombectomy (EVT) is the recommended first-line therapy for large vessel occlusion (LVO), achieving 80-90% recanalization, fewer than 50% of patients reach functional independence (mRS 0-2) due to "futile recanalization" caused by mechanisms like no-reflow and reperfusion injury. Monosialotetrahexosylganglioside (GM1) is a unique glycosphingolipid that crosses the blood-brain barrier to provide neuroprotection by suppressing oxidative stress, excitotoxicity, and apoptosis while promoting neurogenesis. Although Phase III trials like the FOCUS study confirmed GM1's safety and efficacy in AIS populations, its benefit specifically for patients undergoing mechanical thrombectomy remains unkown. Therefore, the IAT-GIANT study is a multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of adjunctive GM1 in improving 90-day functional outcomes for AIS-LVO patients treated with EVT.

03

Conditions studied

  • Stroke
  • Acute Ischemic Stroke

Browse trials for

Keywords

  • GM1
  • Mechanical Thrombectomy
  • Acute Anterior Circulation Large Vessel Occlusion
04

In context

Ischemic Stroke Reclassified

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

This study's planned enrollment of 868 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.

Browse Ischemic Stroke studies →

Lead sponsor

Xuanwu Hospital, Beijing is the lead sponsor of 365 studies on the registry; 231 are open to participants now.

Compared within Ischemic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Age ≥18 years and ≤80 years
  • 2.Symptoms and signs consistent with anterior circulation ischemia;
  • 3.Computed tomography angiography (CTA) /magnetic resonance angiography (MRA) /digital subtraction angiography (DSA) confirmed occlusion of intracranial segment of internal carotid artery (ICA) or M1/M2 segments of the middle cerebral artery (MCA M1/M2);
  • 4.Acute ischemic stroke (AIS) selected for emergency endovascular treatment;
  • 5.Premorbid mRS ≤1;
  • 6.Time from symptom onset to randomization was within 24 hours, including patients with wake-up stroke or unwitnessed stroke; The time of symptom onset was defined as the Last Known Well (LKW);
  • 7.National Institutes of Health Stroke Score (NIHSS) ≥6 at admission;
  • 8.ASPECTS ≥3;
  • 9. obtained from the patient or his/her legal representative.

Exclusion criteria

Exclusion Criteria:

  • 1.Simultaneous acute occlusion of large vessels in both the anterior and posterior circulation or bilateral cerebral hemispheres.
  • 2.Baseline NIHSS is not obtained by a neurologist or emergency physician prior to sedation or intubation;
  • 3.Seizures at stroke onset which would preclude obtaining a baseline NIHSS;
  • 4.Bilateral dilated pupils;
  • 5.Allergy to GM1 or ;
  • 6.Severe contrast allergy or absolute to iodinated contrast;
  • 7.Systolic pressure >185 mmHg or diastolic pressure >110 mmHg, and cannot be controlled by antihypertensive drugs;
  • 8.Blood glucose \<50 mg/dl (2.8 mmol/L) or >400 mg/dl (22.2 mmol/L);
  • 9. \<50*10\^9/L;
  • 10.Known genetic or acquired bleeding diathesis, deficiency of anticoagulant factors, or oral anticoagulant drugs and > 1.7, or treated with direct oral anticoagulant agents in the prior 48 hours;
  • 11.Known Severe renal Failure as defined by a serum creatinine > 3.0 mg/dl (or 265.2 μmol/l) or (GFR) \<30, or patient requires hemodialysis or peritoneal dialysis;
  • 12.Patients that cannot complete 90-day follow-up (e.g. no fixed residence, overseas patients, etc.);
  • 13.Presumed vasculitis or septic embolization;
  • 14.Suspicion of aortic dissection;
  • 15.Evidence indicates intracranial tumors (excluding small meningiomas), acute intracranial hemorrhage, tumors, or arteriovenous malformations (AVMs).
  • 16. Significant mass effect causing midline shift.
  • 17. The patient has neurological disease or mental disorder before onset, which affects the assessment of the condition;
  • 18.Females who are pregnant or in lactation;
  • 19.Hereditary glycolipid metabolic disorders (ganglioside storage diseases, such as familial amaurotic idiocy, retinal degenerative diseases);
  • 20. diseases, spine injuries, demyelinating diseases (e.g., Guillain-Barre syndrome)
  • 21.Participating in other clinical trials that could confound the evaluation of the study;
  • 22.Other circumstances that the investigator considers inappropriate for participation or may pose a significant risk to patients.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
868 participants (estimated)

Study arms

  • Placebo comparator
    Placebo Therapy

    Drug: Placebo Therapy

  • Experimental
    Intravenous GM1 Therapy

    Drug: Intravenous GM1 Therapy

Interventions

  • DrugIntravenous GM1 Therapy

    Patients should receive intravenous administration of GM1 as soon as possible after randomization (Highly recommend within 2 hours.) The GM1 group will receive 200mg daily until day 7 after randomization or hospital discharge by intravenous infusion (Qilu Pharmaceutical Co., Ltd., Jinan, China). GM1 will be dissolved in 100ml normal saline.

  • DrugPlacebo Therapy

    The control group will receive a placebo containing excipients only (without GM1). The placebo will be dissolved in normal saline and administered using the same methods, duration, and dosage regimen as the active treatment group. The appearance, preparation, and administration procedures of the placebo will be identical to those of the investigational drug to ensure blinding.

07

What researchers measure

Primary outcomes

  1. Rate of mRS score of 0-2

    Time frame: 90 days (±7 days) after randomization

Secondary outcomes

  1. Rate of mRS score of 0-1

    Time frame: 90 days (±7 days) after randomization

  2. Rate of mRS score of 0-3

    Time frame: 90 days (±7 days) after randomization

  3. mRS scores (ordinal-shift analysis)

    The modified Rankin Scale (mRS) is an ordinal scale ranging from 0 to 6 that measures the degree of disability or dependence in daily activities after stroke. Higher scores indicate greater disability. 0 No symptoms at all. 1. No significant disability despite symptoms; able to carry out all usual duties and activities. 2. Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance. 3. Moderate disability; requiring some help, but able to walk without assistance. 4. Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance. 5. Severe disability; bedridden, incontinent, and requiring constant nursing care and attention. 6. Dead.

    Time frame: 90 days (±7 days) after randomization

  4. NIHSS Score Change

    The National Institutes of Health Stroke Scale (NIHSS) is a standardized neurological examination scale used to quantify stroke-related neurological deficits and assess stroke severity. The NIHSS evaluates level of consciousness, gaze, visual fields, facial palsy, motor arm and leg function, limb ataxia, sensory function, language, dysarthria, and extinction/inattention. The total NIHSS score is calculated by summing the individual item scores and ranges from 0 to 42, with 0 indicating no neurological deficit and higher scores indicating greater stroke severity. 1a Level of Consciousness 0-3 1b Level of Consciousness Questions 0-2 1. c Level of Consciousness Commands 0-2 2. Best Gaze 0-2 3. Visual Fields 0-3 4. Facial Palsy 0-3 5. a Motor Arm, Left 0-4 5b Motor Arm, Right 0-4 6a Motor Leg, Left 0-4 6b Motor Leg, Right 0-4 7 Limb Ataxia 0-2 8 Sensory 0-2 9 Best Language 0-3 10 Dysarthria 0-2 11 Extinction and Inattention 0-2

    Time frame: 48hours (±48 hours) after randomization

  5. Rate of early neurological improvement

    the NIHSS score 0-1 or decrease ≥4 from baseline NIHSS

    Time frame: 48hours (±12 hours) after randomization

  6. NIHSS Score Change

    The National Institutes of Health Stroke Scale (NIHSS) is a standardized neurological examination scale used to quantify stroke-related neurological deficits and assess stroke severity. The NIHSS evaluates level of consciousness, gaze, visual fields, facial palsy, motor arm and leg function, limb ataxia, sensory function, language, dysarthria, and extinction/inattention. The total NIHSS score is calculated by summing the individual item scores and ranges from 0 to 42, with 0 indicating no neurological deficit and higher scores indicating greater stroke severity. 1a Level of Consciousness 0-3 1b Level of Consciousness Questions 0-2 1. c Level of Consciousness Commands 0-2 2. Best Gaze 0-2 3. Visual Fields 0-3 4. Facial Palsy 0-3 5. a Motor Arm, Left 0-4 5b Motor Arm, Right 0-4 6a Motor Leg, Left 0-4 6b Motor Leg, Right 0-4 7 Limb Ataxia 0-2 8 Sensory 0-2 9 Best Language 0-3 10 Dysarthria 0-2 11 Extinction and Inattention 0-2

    Time frame: 7 days after randomization or discharge

  7. EQ-5D score

    The EQ-5D-5L is a standardized measure of health-related quality of life developed by the EuroQol Group. It consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five response levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses across the five dimensions are combined into a 5-digit health state profile. The EQ VAS records the respondent's self-rated health on a vertical visual analogue scale, with endpoints anchored at 100 = the best health the respondent can imagine and 0 = the worst health the respondent can imagine. EQ-5D health states may be converted into a single index value using an appropriate EQ-5D value set, with higher index values indicating better health status.

    Time frame: 90 days (±7 days) after randomization

  8. Barthel Index

    Time frame: 90 days (±7 days) after randomization

Other outcomes

  1. Rate of any ICH and subtypes

    according to the Heidelberg Classification

    Time frame: within 48 hours after randomization

  2. Rate of sICH

    according to the Heidelberg Definition

    Time frame: within 48 hours after randomization

  3. Mortality

    Time frame: 90 days (±7 days) after randomization

08

Study locations

2 of 2 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jan 2027, 8 months after the start.

Of 76 non-industry phase 4 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 42. This study's planned 8 months is below that.

Counting every sponsor, half of 85 studies reached it within 31 months; a quarter within 24 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2026
First posted
Apr 9, 2026
StartActual
May 14, 2026
Primary completionEst.
Jan 31, 2027
CompletionEst.
Aug 31, 2028
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07519044
Responsible party
Sponsor
First posted
Apr 9, 2026
Start date
May 14, 2026
Primary completion
Jan 31, 2027 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Jun 24, 2026

Study contacts

Xuesong Bai
Contact
bxsben@163.com
Xuanwu Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion